ArticleKidney international2016
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03887416 (Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2018Pooled it
- Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.Diabetes, obesity & metabolism · 2018Pooled it
- Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.Clinical journal of the American Society of Nephrology : CJASN · 2026Trial
- Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention.Saudi medical journal · 2022Trial
- Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.American journal of physiology. Renal physiology · 2018Trial
- Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Diabetes, obesity & metabolism · 2017 · on this mapTrial
- Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Cardiovascular diabetology · 2017 · on this mapTrial
- Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Cardiovascular diabetology · 2016Trial
- Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study.Clinical kidney journal · 2026Article
- A Prospective Cohort Study on the Impact of SGLT2 Inhibitors on the 12‑Month Recurrence Risk of Atrial Fibrillation After Catheter Ablation.Drug design, development and therapy · 2026Observational
- Empagliflozin and fluid balance: results from the SiRENA project.Clinical kidney journal · 2025Article
- Mitochondrial Changes Induced by SGLT2i in Lymphocytes from Diabetic Kidney Transplant Recipients: A Pilot Study.International journal of molecular sciences · 2025Article
- Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications.Current hypertension reports · 2024Review
- Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials.Current oncology reports · 2024Review
- Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores.Journal of pharmaceutical health care and sciences · 2024Article
- Dapagliflozin can alleviate renal fibrosis in rats with streptozotocin‑induced type 2 diabetes mellitus.Experimental and therapeutic medicine · 2023Article
- Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.Cardiovascular diabetology · 2023Article
- Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data.BMJ open · 2022Article
- Role of the adaptive immune system in diabetic kidney disease.Journal of diabetes investigation · 2022Review
- SGLT2 inhibitors, sodium and off-target effects: an overview.Journal of nephrology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibition of sodium-glucose cotransporter 2 causes both glycosuria and natriuresis, leading to reductions in hyperglycemia, body weight, blood pressure, and proteinuria. The recently published EMPA-REG OUTCOME study demonstrated significant cardiovascular and mortality benefits of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with type 2 diabetes and established cardiovascular disease, and may suggest a broader role for sodium-glucose cotransporter 2 inhibition in patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.